Steven Kampa’s Post

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

Recently, the Federal Circuit addressed a significant issue of first impression with respect to obviousness-type double patenting (ODP), holding that ODP applies to patent claims that claim priority to the same application and have different expiration dates due only to patent term adjustment. Read more in the article written by Meghan McLean Poon, Ph.D. and me on the MoFo Life Science Blog.

RSM US LLP senior life sciences analysts Justin Culbertson and Brian Winne's recent industry outlook dive into how patent expirations could lead large biopharmas to invest in the middle market as they renew their patent pipelines. Read more:

USPTO has proposed amending the patent rules around terminal disclaimers to require that the disclaimed patent will only be enforceable if the patent is not tied and has never been tied to a patent held invalid for lack of novelty or obviousness. Comments on the proposed rule are due July 9. If the rule goes into effect, this could have big repercussions for large patent portfolios which are often linked together by terminal disclaimers. Challengers would be able to invalidate one patent, causing a domino effect invalidating other members of the portfolio that have been terminally disclaimed over the challenged patent. Read more in the post by Karen G. Potter and Jeff Schmidt, PhD, MBA, JD on the MoFo Life Sciences Blog. https://lnkd.in/gEk4A66B